Glenmark Azelaic Acid Gel Recall Due to Texture Complaints
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Glenmark Pharmaceuticals Inc., USA is recalling specific lots of Azelaic Acid Gel, 15% due to CGMP deviations involving abnormal texture.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on August 12, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Drugs.
What Happened
Glenmark Pharmaceuticals Inc., USA initiated a voluntary recall of Azelaic Acid Gel, 15% due to CGMP deviations. Product quality complaints were received concerning abnormal texture or consistency described as grainy, gritty, or sandy.
Which Products Are Affected
The recall affects Azelaic Acid Gel, 15%, 50 gram tubes, For Topical Use only, Rx only, NDC 68462-626-52. Affected lots include: 19260937A (Exp. February 2028); 19261225A and 19261185A (Exp. March 2028); 19261664A and 19261682A (Exp. April 2028). Distribution was nationwide within the United States.
What You Should Do
Consumers should check the lot number and expiration date on their product against the listed affected lots.
Why This Matters
This Class II recall addresses potential quality issues with a prescription topical drug distributed nationwide.
Source
FDA recall number D-0731-2026. Data from FDA enforcement records.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.